生物技术通报 ›› 2025, Vol. 41 ›› Issue (5): 62-69.doi: 10.13560/j.cnki.biotech.bull.1985.2024-0955

• 技术与方法 • 上一篇    下一篇

RPA-CRISPR/Cas12a结合重力驱动微流控芯片的MTB快检方法的建立

高畅1(), 庄添驰2, 李宁3, 刘云4, 顾鹏飞1, 赵昕怡5, 季明辉2()   

  1. 1.南京医科大学第二临床医学院,南京 211166
    2.南京医科大学护理学院,南京 211166
    3.南京市江宁区疾病预防控制中心,南京 211100
    4.南京市秦淮区疾病预防控制中心,南京 210001
    5.南京医科大学第一临床医学院,南京 211166
  • 收稿日期:2024-09-30 出版日期:2025-05-26 发布日期:2025-06-05
  • 通讯作者: 季明辉,男,博士,副教授,研究方向 :病原体检测;E-mail: jiminghui@njmu.edu.cn
  • 作者简介:高畅,女,研究方向 :病原体检测;E-mail: 1975480691@qq.com
  • 基金资助:
    ?:江苏省卫生健康委员会预防医学科研课题面上项目(Ym2023064);国家级大学生创新创业训练计划基金项目(202410312005Z);南京预防医学科研课题(NJYFKT202409);江苏高校优势学科建设工程四期项目“护理学”(苏教研函〔2023〕11号)

Gravity-driven Microfluidic Chip Based on RPA-CRISPR/Cas12a for the Rapid Detection of Mycobacterium tuberculosis

GAO Chang1(), ZHUANG Tian-chi2, LI Ning3, LIU Yun4, GU Peng-fei1, ZHAO Xin-yi5, JI Ming-hui2()   

  1. 1.Second Clinical Medical College, Nanjing Medical University, Nanjing 211166
    2.School of Nursing, Nanjing Medical University, Nanjing 211166
    3.Jiangning District Center for Disease Control and Prevention, Nanjing 211100
    4.Qinhuai District Center for Disease Control and Prevention, Nanjing 210001
    5.First Clinical Medical College, Nanjing Medical University, Nanjing 211166
  • Received:2024-09-30 Published:2025-05-26 Online:2025-06-05

摘要:

目的 开发一种快速高效的结核分枝杆菌(MTB)检测方法,给基层单位、偏远地区的结核病(Tuberculosis)快速筛查提供技术方案,更好地开展结核病的防治工作。 方法 设计RPA引物、crRNA,并引入重力驱动的微流控芯片,建立RPA-CRISPR/Cas12a的片上检测方法,进一步分析该方法的灵敏度与特异性,使用疑似结核病患者的样本进行片上检测和痰培养,比较建立的方法与痰培养法的一致性。 结果 建立的RPA-CRISPR/Cas12a片上检测方法可在30 min内实现MTB检测,LOD为1 copies/μL。以痰培养鉴定为参考标准,片上检测法的灵敏度为91.11%,特异度为94.34%,阳性预测值为93.19%,阴性预测值为92.59%,准确性为92.86%,Kappa值为0.856。 结论 建立的RPA-CRISPR/Cas12a的片上检测法的灵敏度、特异性高,并且快速、简单、便捷。

关键词: 结核分枝杆菌, 重组酶聚合酶扩增, CRISPR/Cas12a, 微流控芯片, 快速检测

Abstract:

Objective To develop a rapid and efficient method for detecting Mycobacterium tuberculosis (MTB), providing a technical solution for rapid screening of tuberculosis (TB) in grassroots units and remote areas, thereby enhancing TB prevention and control efforts. Method RPA (recombinase polymerase amplification) primers and crRNA were designed, and a gravity-driven microfluidic chip was introduced to establish an RPA-CRISPR/Cas12a on-chip detection method. The sensitivity and specificity of this method were further analyzed using samples from suspected TB patients for on-chip detection and sputum culture, comparing the established method with the sputum culture method for consistency. Result The established RPA-CRISPR/Cas12a on-chip detection method achieves MTB detection within 30 min, with a limit of detection (LOD) of 1 copy/μL. Using sputum culture identification as a reference standard, the on-chip detection method demonstrated a sensitivity of 91.11%, specificity of 94.34%, positive predictive value of 93.19%, negative predictive value of 92.59%, and accuracy of 92.86%, with a Kappa value of 0.856. Conclusion The developed RPA-CRISPR/Cas12a on-chip detection method presents high sensitivity and specificity, characterized by rapid, simple, and convenient.

Key words: Mycobacterium tuberculosis, RPA, CRISPR/Cas12a, microfluidics chip, rapid detection